Korean J Med.
2008 Apr;74(4):366-367.
Systemic drug therapy and restenosis after drug-eluting stent implantation
- Affiliations
-
- 1Department of Internal Medicine, College of Medicine, Hallym University, Seoul, Korea.
Abstract
- Until now restenosis is one of the most important issues after stent implantation. Use of systemic drug therapy to inhibit post-stent restenosis has been largely unsuccessful. Drug-eluting stents (DES) have been shown to significantly reduce restenosis after percutaneous coronary intervention. However we still experience lots of problems associated with restenosis even after DES implantation. Recently some clinical trials have suggested that cilostazol reduces intimal hyperplasia and lowers restenosis after bare metal stents (BMS) implantation. It is uncertain that cilostazol can also reduce restenosis after DES implantation. We need more large clinical trials to elucidate the efficacy of cilostazol on restenosis after DES implantation.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Drug-Eluting Stent Strut Fracture as a Cause of Restenosis
- Coronary Restenosis after Drug-Eluting Stent Implantation in Diabetic Patients
- A Case of Stent Thrombosis Occurred at 5 Years after Sirolimus-Eluting Stent Implantation
- A Case of Stent Strut Fracture of a Paclitaxel-Eluting Stent at the Time of Stent Implantation in a Complex Coronary Lesion
- Predictive Factors for Restenosis after Drug-Eluting Stent Implantation
